Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BLRX $1.48 0.1500 +11.28%
DRNA $14.47 1.1100 +8.31%
TGTX $14.18 1.0000 +7.59%
MNKD $2.13 0.1300 +6.50%
NWBO $4.90 0.2800 +6.06%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

KITE $76.05 -6.3200 -7.67%
OMED $21.18 -1.6700 -7.31%
ARGS $3.79 -0.2800 -6.88%
RDUS $56.80 -4.0100 -6.59%
LOXO $30.91 -2.0200 -6.13%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Advanced Disease Missed Without PSA Testing?

(MedPage Today/The Gupta Guide) Nov 30, 2015 - New prostate cancer diagnoses declined by almost 30% in the first year after the U.S. Preventive Services Task Force (USPSTF) recommended against routine screening PSA tests, a review of a national database showed.
read article (free registration required) 

Men Who Forgo Aggressive Treatment For Prostate Cancer Don't Receive Appropriate Monitoring

(UCLA) Dec 1, 2015 - A new study by UCLA researchers has found that less than 5 percent of men who chose to forgo aggressive treatment are being monitored as closely as they should be, putting them in danger of their cancer progressing or metastasizing without their knowledge.
read press release 

Recurrence Score Assay Sways Tx Use in Early Breast Ca

(MedPage Today) Nov 30, 2015 - The 21-gene recurrence score (RS) assay in women with early-stage breast cancer substantially influenced recommendations for when to proceed with adjuvant chemotherapy and when to avoid it, according to two studies.
read article (free registration required) 

Female Hormone Supplements with Estrogen and Progestin Linked to Higher Risk of Estrogen Receptor Positive Breast Cancer in African American Women

(Boston University) Nov 30, 2015 - Postmenopausal African American women who use female hormone supplements containing estrogen and progestin ("combination" therapy) are at an increased risk for estrogen receptor positive breast cancer.
read press release 

China to Have Over 800,000 Lung Cancer Patients a Year by 2020, State Media Says

(Time) Dec 1, 2015 - China will likely see an increase in the prevalence of lung cancer among its population over the next five years, the state-run China Daily reports.
read article 

Why the U.S. Pays More Than Other Countries for Drugs

(Wall Street Journal) Nov 30, 2015 - A vial of the cancer drug Rituxan cost Norway’s taxpayer-funded health system $1,527 in the third quarter of 2015, while the U.S. Medicare program paid $3,678.
read article (paid subscription required) 

Roche Pulls Out Of 'Superbug' Antibiotic Project

(Reuters) Nov 29, 2015 - Swiss drugmaker Roche Holding has dropped out of a high-profile project to develop an antibiotic for treating "superbug" infections, the company said on Sunday.
read article 

Pfizer to Take Stake in Sosei, Collaborate With Heptares

(Bloomberg) Nov 30, 2015 - Pfizer Inc. agreed to buy a 3 percent stake in Sosei Group Corp. and enter into a drug-discovery collaboration with the Japanese company’s U.K. unit to develop new medicines aimed at a handful of biological targets that may play a role in multiple diseases.
read article 

Amgen Files For U.S. Approval Of Biosimilar To Humira

(Reuters) Nov 25, 2015 - Amgen Inc on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie's Humira, the world's top-selling prescription medicine.
read article 

Reimbursement Policy for Biosimilars Will Have Negative Consequences for Patients

(American Action Forum) Nov 24, 2015 - The Centers for Medicare and Medicaid Services (CMS) have finalized a rule regarding the Medicare reimbursement methodology for biosimilar products.
read article 

Hospitals Form Patient Advisory Councils to Learn How They Can Improve Care

(Wall Street Journal) Nov 29, 2015 - The panels work on projects and policies along with hospital staff—and may help hospitals score higher in measures of patient satisfaction.
read article (paid subscription required) 

Working to Lower Drug Costs by Challenging Questionable Patents

(New York Times) Nov 27, 2015 - The Coalition for Affordable Drugs goes after pharmaceutical companies that it says exploit the patent system to keep prices and profits high.
read article 

New Grant Opportunity Available From Neuroendocrine Tumor Research Foundation-American Association for Cancer Research

(AACR) Nov 24, 2015 - The American Association for Cancer Research (AACR) and the Neuroendocrine Tumor Research Foundation are pleased to announce a new grant opportunity.
read press release 

Major Shareholder Wants Inquiry Into Northwest Biotherapeutics Allegations

(Wall Street Journal) Nov 28, 2015 - A major shareholder is urging biotechnology firm Northwest Biotherapeutics to hold an inquiry into allegations about the governance of the company by Chairwoman and Chief Executive Linda Powers.
read article (paid subscription required) 

Five Key Issues For Future Cancer Care And Health Informatics

(Forbes) Nov 30, 2015 - Oncology IT will harness information from millions of cancer patients, now and in years ahead, connect the dots, and – as new medications arrive from the pipeline – nudge doctors and patients toward optimal treatments.
read article 

Deadline to Check on PQRS Incentive Payments Further Extended to Dec. 16

(ASCO in Action) Nov 25, 2015 - For a second time, the Centers for Medicare & Medicaid Services (CMS) has extended the deadline for eligible individuals and groups that believe they have been incorrectly identified for the 2016 Physician Quality Reporting System (PQRS) negative payment adjustment to submit an informal review request.
read article 

Informal Review Requests of the 2016 Value Modifier Due to CMS by Dec. 16

(ASCO in Action) Nov 25, 2015 - The Centers for Medicare & Medicaid Services is currently accepting informal requests to review the 2016 Value Modifier.
read article 

The American Society of Hematology and McMaster University Announce Partnership to Develop Clinical Practice Guidelines on Venous Thromboembolism

(ASH) Nov 30, 2015 - Guidelines on the treatment and diagnosis of VTE anticipated In 2017.
read press release 

What Hematologists Need to Know about the Medicare Merit-based Incentive Payment System

(ASH) Nov 24, 2015 - Good to understand MACRA – but don’t panic (Part 1).
read article 

BioLight, Axella to Advance CellDetect In Bladder Cancer

(BioTuesdays) Nov 30, 2015 - BioLight Life Sciences Investments’ cancer diagnostics subsidiary, Micromedic Technologies, has entered into a collaboration agreement with Axella Research to advance the clinical and regulatory requirements to commercialize BioLight’s CellDetect non-invasive diagnostic test for monitoring bladder cancer recurrence in the U.S.
read article 

Exact Sciences Addresses CMS’s 2016 Clinical Diagnostic Laboratory Fee Schedule

(Exact Sciences) Nov 27, 2015 - On November 25, 2015, the Centers for Medicare and Medicaid Services (CMS) posted the 2016 Clinical Diagnostic Laboratory Fee Schedule (CLFS) on its website.
read corporate press release 

FDA Clears Siemens CT Scanners for Low-Dose Lung Cancer Screening

(Siemens USA) Nov 30, 2015 - The Food and Drug Administration (FDA) has cleared Siemens Healthcare’s SOMATOM computed tomography (CT) systems for low-dose lung cancer screening.
read corporate press release 

Aetna Expert Explores New Cancer Payment Methodology

(Managed Healthcare Executive) Nov 29, 2015 - New payment models that were initially developed for primary care or common surgical procedures are now being developed and used for patients with blood diseases.
read article 

Ignyta and EORTC Announce Entrectinib Selected as First Investigational Cancer Agent to be Included in EORTC SPECTA Precision Medicine Clinical Trial Program

(Yahoo! Finance) Nov 30, 2015 - Ignyta, Inc., a precision oncology biotechnology company, and the European Organisation for Research and Treatment of Cancer (EORTC) today announced that they will collaborate via EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) biomarker screening initiative to identify patients who harbor a gene rearrangement to NTRK1, NTRK3, ROS1 or ALK and therefore may be eligible for Ignyta’s global STARTRK-2 Phase 2 clinical study.
read article 

NCCN Collaborates With Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer

(NCCN) Nov 30, 2015 - NCCN is collaborating with Bristol-Myers Squibb to promote the advancement of scientific knowledge concerning programmed death-ligand 1 (PD-L1) protein expression and other immune markers in lung cancer.
read press release